Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.

Open True Mainstream to compare left, right, and center coverage

1,600+ newsrooms tracked, in English, around the clock. Real newsrooms only — no NGOs, no press releases. Left/Right tags come from reader feedback. No algorithmic feed.